rituximab,etoposide,axicabtagene ciloleucel,carboplatin,ifosfamide,polatuzumab vedotin,vedolizumab,lisocabtagene maraleucel
roche,takeda,bms,gilead,daiichi sankyo
['zuma-7', 'polatuzumab', 'transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'ritux', 'etoposide', 'carboplatin', 'ifosfa', ' pola ', 'dlbcl', ' vedo']
#ash22
abstract 442 - alex herrera et al. polar-ice followed by polatuzumab consolidation as a new salvage treatment option in r/r dlbcl? after 2 cycles, the orr was 88%
at the end of salvage, crr was 56% a study comparing polar-ice to r-ice is ongoing. 
Hematologist at Saint Antoine Hospital, Paris, France @Sorbonne_Univ_ @APHP. @JACIE_EBMT National Representative. #BMTsm #LYMsm #CARTcell #CardioOnc #QoL